Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46

Iovance Biotherapeutics 7.69M share Secondary priced at $6.50

The deal priced at $6.50, below today's closing price of $7.15, which was a decline of over 16% on the trading day. Iovance Biotherapeutics intends to use the net proceeds from this offering to fund its current and future clinical trials for its product candidates, including its ongoing Phase 2 clinical trials of LN-144, TIL for treatment of metastatic melanoma, and LN-145, TIL for the treatment of cervical and head and neck cancers, to fund activities related to commercial scale-up of the company's TIL product manufacturing operations; and for working capital and other general corporate purposes. Jefferies and Wells Fargo acted as joint book running managers for the offering.

  • 25

    Sep

  • 21

    Sep

IOVA Iovance Biotherapeutics
$7.15

-1.4 (-16.37%)

08/03/17
OPCO
08/03/17
INITIATION
Target $13
OPCO
Outperform
Iovance Biotherapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Iovance Biotherapeutics with an Outperform and a $13 price target saying its tumor infiltrating lymphocytes therapy has been clinically validated by several academic institutions and expects to see a stream of clinical readouts from three ongoing company-sponsored trials in the next 12-18 month. Breidenbach expects lovance's path to commercialization in solid tumors to be simplified due to to the trailblazing of personalized CAR-T therapies for blood cancers.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.

TODAY'S FREE FLY STORIES

02:40
12/12/17
12/12
02:40
12/12/17
02:40
General news
FX Update: Narrow ranges have prevailed »

FX Update: Narrow ranges…

01:55
12/12/17
12/12
01:55
12/12/17
01:55
General news
FX Action: USD-JPY has plied a narrow 14 pip range »

FX Action: USD-JPY has…

NAV

Navistar

$40.07

0.17 (0.43%)

20:13
12/11/17
12/11
20:13
12/11/17
20:13
Upgrade
Navistar rating change at Stifel »

Navistar upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

GBT

Global Blood Therapeutics

$44.78

-0.925 (-2.02%)

20:10
12/11/17
12/11
20:10
12/11/17
20:10
Conference/Events
Global Blood Therapeutics to hold an investor webcast »

Management reviews the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

VMW

VMware

$121.09

1.52 (1.27%)

19:55
12/11/17
12/11
19:55
12/11/17
19:55
Conference/Events
VMware management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 17

    Jan

MMC

Marsh & McLennan

$83.93

-0.2 (-0.24%)

19:52
12/11/17
12/11
19:52
12/11/17
19:52
Conference/Events
Marsh & McLennan management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

BG

Bunge

$69.67

-0.12 (-0.17%)

19:48
12/11/17
12/11
19:48
12/11/17
19:48
Conference/Events
Bunge management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

COP

ConocoPhillips

$51.69

0.12 (0.23%)

19:42
12/11/17
12/11
19:42
12/11/17
19:42
Conference/Events
ConocoPhillips management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

BL

BlackLine

$35.04

0.37 (1.07%)

19:36
12/11/17
12/11
19:36
12/11/17
19:36
Conference/Events
BlackLine management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 26

    Feb

AGIO

Agios Pharmaceuticals

$61.42

0.45 (0.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Agios Pharmaceuticals to hold an investor meeting »

Investor Meeting where…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SGEN

Seattle Genetics

$55.27

-3.995 (-6.74%)

19:25
12/11/17
12/11
19:25
12/11/17
19:25
Conference/Events
Seattle Genetics to hold an investor and analyst event »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 16

    Dec

TCBK

TriCo Bancshares

$41.34

-0.3 (-0.72%)

19:15
12/11/17
12/11
19:15
12/11/17
19:15
Hot Stocks
TriCo to acquire FNB in transaction valued at roughly $315.3M »

TriCo Bancshares and FNB…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:53
12/11/17
12/11
18:53
12/11/17
18:53
Hot Stocks
Archrock Partners LP names Raymond Guba interim CFO of general partner »

Archrock Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AROC

Archrock

$9.80

0.3 (3.16%)

, APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

18:49
12/11/17
12/11
18:49
12/11/17
18:49
Hot Stocks
Archrock names Raymond Guba Interim CFO »

Archrock announced that…

AROC

Archrock

$9.80

0.3 (3.16%)

APLP

Archrock Partners LP

$11.41

0.19 (1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAV

Advantage Oil & Gas

$4.05

0.05 (1.25%)

18:33
12/11/17
12/11
18:33
12/11/17
18:33
Hot Stocks
Advantage Oil & Gas announces 2018 capital budget of $175M »

Advantage Oil & Gas…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

18:22
12/11/17
12/11
18:22
12/11/17
18:22
Upgrade
Rosneft rating change at Goldman Sachs »

Rosneft upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$24.85

-1.11 (-4.28%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Recommendations
Glaukos analyst commentary at Piper Jaffray »

Piper sees 'another…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FATE

Fate Therapeutics

$4.14

-0.03 (-0.72%)

18:18
12/11/17
12/11
18:18
12/11/17
18:18
Hot Stocks
Fate Therapeutics reports Day 100 results from Phase 1 stage of PROTECT trial »

Fate Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

GM

General Motors

$41.67

-0.35 (-0.83%)

18:14
12/11/17
12/11
18:14
12/11/17
18:14
Periodicals
GM CEO: Cutting EV tax credit 'will have an impact' on sales, Reuters says »

General Motors CEO Mary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 16

    Jan

EDIT

Editas Medicine

$23.60

-1.36 (-5.45%)

18:02
12/11/17
12/11
18:02
12/11/17
18:02
Hot Stocks
Editas Medicine reports results from expanded CRISPR genome editing strategies »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FMBH

First Mid-Illinois Bancshares

$39.09

0.42 (1.09%)

18:00
12/11/17
12/11
18:00
12/11/17
18:00
Hot Stocks
First Mid-Illinois Bancshares to acquire First BancTrust Corp for $73.8M »

First Mid-Illinois…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVX

Chevron

$120.42

0.5 (0.42%)

17:46
12/11/17
12/11
17:46
12/11/17
17:46
Initiation
Chevron initiated  »

Chevron initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPOR

Gulfport Energy

$13.13

0.67 (5.38%)

17:44
12/11/17
12/11
17:44
12/11/17
17:44
Initiation
Gulfport Energy initiated at Credit Suisse »

Gulfport Energy initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$57.13

0.75 (1.33%)

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Initiation
EQT Corporation initiated at Credit Suisse »

EQT Corporation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BTC

Bitcoin

, BITCOIN

Bitcoin

17:43
12/11/17
12/11
17:43
12/11/17
17:43
Hot Stocks
SEC Chairman says no initial coin offerings have been registered »

Securities and Exchange…

BTC

Bitcoin

BITCOIN

Bitcoin

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.